New Ph III Xarelto study shows superiority over aspirin to prevent blood clots
German pharma major Bayer (BAYN: DE) and it is development partner Janssen Pharmaceuticals have announced positive new Phase III results from EINSTEIN CHOICE in patients with venous thromboembolism (VTE) taking Xarelto (rivaroxaban) who received either 10mg or 20mg once daily over an extended time period.
The results, presented at the American College of Cardiology (ACC) annual scientific session over the weekend, showed that patients give the drug had significantly fewer recurrent blood clots and similar rates of major bleeding compared to those taking aspirin 100 mg once daily. Specifically, Xarelto 10mg reduced the risk of recurrent VTE by 74% and Xarelto 20mg by 66%.
EINSTEIN CHOICE is part of the industry-leading EXPLORER clinical research program for Xarelto, a collaborative effort between Janssen, a subsidiary of US healthcare giant Johnson & Johnson (NYSE: JNJ), and Bayer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze